Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tridihexethyl is a synthetic anticholinergic and antimuscarinic small molecule drug that was primarily used as its chloride salt. It acts as an antagonist at muscarinic acetylcholine receptors (M1, M2, and M3 subtypes), thereby inhibiting the action of acetylcholine on these receptors. This results in pronounced antispasmodic and antisecretory effects on the gastrointestinal tract by reducing vagally mediated reflexes and gastric acid secretion. Tridihexethyl was indicated as an adjunct in the treatment of peptic ulcer disease and has also been studied for acquired nystagmus. The drug is no longer available in the US market due to side effects and limited use[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tridihexethyl.